Pfizer Cashes in on COVID Vaccine, Announces Soaring Profits Smashed Expectations

COVID-19 vaccine and treatment sales helped Pfizer breeze past Wall Street’s first-quarter expectations, as the drugmaker’s profit grew 61 percent.
The coronavirus vaccine Comirnaty, which has been Pfizer’s top seller for about a year, brought in more than $13 billion in sales in the first quarter. The pill treatment Paxlovid, which launched late last year, brought in another $1.5 billion.
All that helped company revenue swell 77 percent, compared to last year’s quarter,